Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

The Female Health Company (FHCO): What We’re Looking For

Investors love stocks that consistently beat the Street without getting ahead of their fundamentals and risking a meltdown. The best stocks offer sustainable market-beating gains, with robust and improving financial metrics that support strong price growth. Does The Female Health Company (NASDAQ:FHCO) fit the bill? Let’s take a look at what its recent results tell us about its potential for future gains.

The Female Health Company (NASDAQ:FHCO)

What we’re looking for
The graphs you’re about to see tell The Female Health Company (NASDAQ:FHCO)’s story, and we’ll be grading the quality of that story in several ways:

  • Growth: Are profits, margins, and free cash flow all increasing?
  • Valuation: Is share price growing in line with earnings per share?
  • Opportunities: Is return on equity increasing while debt to equity declines?
  • Dividends: Are dividends consistently growing in a sustainable way?

What the numbers tell you
Now, let’s take a look at The Female Health Company (NASDAQ:FHCO)’s key statistics:

FHCO Total Return Price Chart

FHCO Total Return Price data by YCharts.

Passing Criteria 3-Year* Change Grade
Revenue growth >30% 63.8% Pass
Improving profit margin 178% Pass
Free cash flow growth >Net income growth 404.5% vs. 355.3% Pass
Improving EPS 362.8% Pass
Stock growth (+ 15%) <EPS growth 94.4% vs. 362.8% Pass

Source: YCharts. * Period begins at end of Q2 2010.

FHCO Return on Equity Chart

FHCO Return on Equity data by YCharts.

Passing Criteria 3-Year* Change Grade
Improving return on equity 122.1% Pass
Declining debt to equity No debt Pass
Dividend growth >25% 40% Pass
Free cash flow payout ratio <50% 52.8% Fail

Source: YCharts. * Period begins at end of Q2 2010.

How we got here and where we’re going
The Female Health Company (NASDAQ:FHCO) comes through with flying colors, missing out on a perfect score only due to an elevated free cash flow payout ratio, which has been in steady decline over the last three years — we could see a perfect score in 2014. Over the past three years, The Female Health Company (NASDAQ:FHCO)’s revenues and earnings have been increasing rapidly, and its share price has actually lagged this fundamental growth. This is a very strong performance, but can The Female Health Company (NASDAQ:FHCO) keep up its progress? Let’s dig a little deeper to find out.

In 2011, an estimated 1.7 million people died due to HIV/AIDS and other sexually transmitted diseases, and more than 2.5 million new cases of HIV-infected people were reported. The U.S. government spent $28 billion in 2012 to fight HIV/AIDS through various health awareness campaigns and providing medical treatment to HIV-infected people. Many Asian and African countries have been affected, which has cost many lesser-developed countries in terms of economic growth and population health in recent years. However, the last decade has seen a drop in the number of new HIV infections around the world.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.